113 related articles for article (PubMed ID: 26134042)
1. Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids.
Cervantes-Madrid D; Dueñas-González A
Oncol Rep; 2015 Sep; 34(3):1533-42. PubMed ID: 26134042
[TBL] [Abstract][Full Text] [Related]
2. Mouse Model for Efficient Simultaneous Targeting of Glycolysis, Glutaminolysis, and De Novo Synthesis of Fatty Acids in Colon Cancer.
Schcolnik-Cabrera A; Dueñas-Gonzalez A
Methods Mol Biol; 2021; 2174():45-69. PubMed ID: 32813244
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and antitumor efficacy
Cervantes-Madrid D; Dominguez-Gomez G; Gonzalez-Fierro A; Perez-Cardenas E; Taja-Chayeb L; Trejo-Becerril C; Duenas-Gonzalez A
Oncol Lett; 2017 Mar; 13(3):1905-1910. PubMed ID: 28454342
[TBL] [Abstract][Full Text] [Related]
4. A combination of inhibitors of glycolysis, glutaminolysis and
Schcolnik-Cabrera A; Dominguez-Gómez G; Chávez-Blanco A; Ramírez-Yautentzi M; Morales-Bárcenas R; Chávez-Díaz J; Taja-Chayeb L; Dueáas-González A
Oncol Lett; 2019 Dec; 18(6):6909-6916. PubMed ID: 31788130
[TBL] [Abstract][Full Text] [Related]
5. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
Cervantes-Madrid D; Romero Y; Dueñas-González A
Biomed Res Int; 2015; 2015():690492. PubMed ID: 26425550
[TBL] [Abstract][Full Text] [Related]
6. The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells.
Schcolnik-Cabrera A; Chavez-Blanco A; Dominguez-Gomez G; Juarez M; Lai D; Hua S; Tovar AR; Diaz-Chavez J; Duenas-Gonzalez A
Oncol Lett; 2020 Sep; 20(3):3053-3060. PubMed ID: 32782623
[TBL] [Abstract][Full Text] [Related]
7. Targeting cellular metabolism to improve cancer therapeutics.
Zhao Y; Butler EB; Tan M
Cell Death Dis; 2013 Mar; 4(3):e532. PubMed ID: 23470539
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy.
Schcolnik-Cabrera A; Chavez-Blanco A; Dominguez-Gomez G; Juarez M; Vargas-Castillo A; Ponce-Toledo RI; Lai D; Hua S; Tovar AR; Torres N; Perez-Montiel D; Diaz-Chavez J; Duenas-Gonzalez A
Sci Rep; 2021 Mar; 11(1):5222. PubMed ID: 33664364
[TBL] [Abstract][Full Text] [Related]
9. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
10. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
Lupu R; Menendez JA
Endocrinology; 2006 Sep; 147(9):4056-66. PubMed ID: 16809439
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer drugs targeting fatty acid synthase (FAS).
Pandey PR; Liu W; Xing F; Fukuda K; Watabe K
Recent Pat Anticancer Drug Discov; 2012 May; 7(2):185-97. PubMed ID: 22338595
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis.
Menendez JA; Colomer R; Lupu R
Med Hypotheses; 2005; 64(2):337-41. PubMed ID: 15607568
[TBL] [Abstract][Full Text] [Related]
14. Fatty acid synthase: a metabolic oncogene in prostate cancer?
Baron A; Migita T; Tang D; Loda M
J Cell Biochem; 2004 Jan; 91(1):47-53. PubMed ID: 14689581
[TBL] [Abstract][Full Text] [Related]
15. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy.
Schcolnik-Cabrera A; Chávez-Blanco A; Domínguez-Gómez G; Taja-Chayeb L; Morales-Barcenas R; Trejo-Becerril C; Perez-Cardenas E; Gonzalez-Fierro A; Dueñas-González A
Expert Opin Investig Drugs; 2018 May; 27(5):475-489. PubMed ID: 29723075
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer.
Akins NS; Nielson TC; Le HV
Curr Top Med Chem; 2018; 18(6):494-504. PubMed ID: 29788892
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers.
Uddin S; Siraj AK; Al-Rasheed M; Ahmed M; Bu R; Myers JN; Al-Nuaim A; Al-Sobhi S; Al-Dayel F; Bavi P; Hussain AR; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Oct; 93(10):4088-97. PubMed ID: 18682509
[TBL] [Abstract][Full Text] [Related]
19. Action at a distance: allostery and the development of drugs to target cancer cell metabolism.
DeLaBarre B; Hurov J; Cianchetta G; Murray S; Dang L
Chem Biol; 2014 Sep; 21(9):1143-61. PubMed ID: 25237859
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of novel beta-lactone inhibitors of fatty acid synthase.
Richardson RD; Ma G; Oyola Y; Zancanella M; Knowles LM; Cieplak P; Romo D; Smith JW
J Med Chem; 2008 Sep; 51(17):5285-96. PubMed ID: 18710210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
